UBS Group’s Soleno Therapeutics, Inc. Series A Warrant SLNOW Stock Holding History

UBS Group’s Portfolio SLNOW Stock Details SLNOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,523	Closed	–	–	8802
2019 Q3	$0	Hold	5,523	–	–	﹤0.01%	8603
2019 Q2	$1K	Hold	5,523	–	–	﹤0.01%	7808
2019 Q1	$1K	Sell	5,523 -5,250	-49%	-$886	﹤0.01%	7652
2018 Q4	$0	Hold	10,773	–	–	﹤0.01%	8696
2018 Q3	$1K	Buy	10,773 +455	+4%	+$100	﹤0.01%	7930
2018 Q2	$3K	Sell	10,318 -100	-1%	-$32	﹤0.01%	7692
2018 Q1	$1K	Hold	10,418	–	–	﹤0.01%	7737
2017 Q4	$2K	Hold	10,418	–	–	﹤0.01%	7671
2017 Q3	$6K	Buy	10,418 +8,559	+460%	+$4.99K	﹤0.01%	7189
2017 Q2	$2K	Buy	+1,859	New	+$1.7K	﹤0.01%	7449

UBS Group's SLNOW Position: Q4 2019 in Review

UBS Group sold out of Soleno Therapeutics, Inc. Series A Warrant (SLNOW) in Q4 2019, closing a stake of 5,523 shares.

UBS Group first reported a position in SLNOW in Q2 2017 and held it in 10 quarters. The position peaked at $6K in Q3 2017. 0 funds tracked by Wall St. Rank hold SLNOW as of Q4 2019.

UBS Group reported no remaining Soleno Therapeutics, Inc. Series A Warrant position as of Q4 2019 after selling out during the quarter.
UBS Group sold 5,523 Soleno Therapeutics, Inc. Series A Warrant shares in Q4 2019.
UBS Group first reported a position in Soleno Therapeutics, Inc. Series A Warrant in Q2 2017 and held it in 10 quarters.
UBS Group's Soleno Therapeutics, Inc. Series A Warrant position peaked at $6K in Q3 2017.
0 funds tracked by Wall St. Rank held Soleno Therapeutics, Inc. Series A Warrant as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.